Whilst radiological and pathological concordance of pCR is still not optimal and appears significantly impacted by subtype, with 67% sensitivity and 85% specificity for TNBC compared with 60% sensitivity and 74% specificity in HR‐positive/HER2‐positive breast cancer, pathological assessment remains a critical component for patient prognostication [4]. Here, ERBB2 is linked to breast cancer.